Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CHKA | P35790 | 1/20 | 0.52 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.50 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.39 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.39 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31040426 | 1.00 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| SCHEMBL32689447 | 0.97 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL31505510 | 0.97 | CA2 (0.52) | CA2CA12CA1CA9CHKA | |
| SCHEMBL6961568 | 0.97 | — | — | |
| SCHEMBL15319 | 0.97 | — | — | |
| SCHEMBL17100538 | 0.97 | CA2 (0.56) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL125486 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| Ammonia Solution, Strong SCHEMBL4674734 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL1408979 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA | |
| Hydrochloric Acid SCHEMBL18116041 | 0.94 | CA2 (0.54) | CA2CA12CA1CA9CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637398-B2 | Radiohalogen prosthetic moieties and radiolabeled biomolecules | DUKE UNIVERSITY (US) | 2026-05-26 | — | — | US | disclosed |
| CN-119192092-B | Water-soluble signal enhanced high-fluorine-content molecular imaging probe and preparation method thereof | 厦门大学 | 2025-10-14 | — | — | CN | disclosed |
| EP-4529540-A1 | HER2-BINDING AGENTS AND USES THEREOF | Cereius, Inc. (US) | 2025-04-02 | — | — | EP | disclosed |
| CN-119604536-A | HER2 binding agents and uses thereof | 塞雷乌斯股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119192092-A | Water-soluble signal enhanced high-fluorine-content molecular imaging probe and preparation method thereof | 厦门大学 | 2024-12-27 | — | — | CN | disclosed |
| WO-2023230488-A1 | HER2-BINDING AGENTS AND USES THEREOF | CEREIUS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| US-20230002293-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | UNIV DUKE (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4058423-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | Duke University (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2021096968-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | DUKE UNIVERSITY (US) | 2021-05-20 | — | — | WO | disclosed |
| US-6770020-B2 | NEUTRON CAPTURE THERAPY (NCT) USING GADOLINIUM DIETHYLENETRIAMINEPENTAACETIC ACID; TREATING GLIOBLASTOMAS, GLIOMAS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2004-08-03 | — | — | US | disclosed |
| US-20030049202-A1 | Method of using gadolinium neutron capture to treat cancers | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2003-03-13 | — | — | US | disclosed |
| US-5573752-A | Aromatic amide compounds and metal chelates thereof | BRACCO INTERNATIONAL B.V. | 1996-11-12 | — | — | US | disclosed |
| WO-1995027705-A1 | AROMATIC AMIDE COMPOUNDS AND METAL CHELATES THEREOF | BRACCO INTERNATIONAL B.V. (NL) | 1995-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002293-A1 | RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULES | CD47, SHBG, KLK3 | CA2 2680/4885CA12 187/4885CA1 1260/4885 |
| US-20030049202-A1 | Method of using gadolinium neutron capture to treat cancers | NUCB2, MKI67, GMNN | CA2 212/4885CA12 229/4885CA1 304/4885 |
| US-12637398-B2 | Radiohalogen prosthetic moieties and radiolabeled biomolecules | CD47, KLK3, SHBG | CA2 3256/4885CA12 252/4885CA1 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.